Close
CDMO Safety Testing 2026
Novotech

Digital Science welcomes Gigantum and Ripeta to the family to help increase reproducibility in research

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access the Media Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Related stories

QIAGEN and NVIDIA Join Forces to Advance AI-Driven Drug Discovery

QIAGEN's Digital Insights bioinformatics division is set to integrate...

Bioprocess Analytics Improving Biologics Manufacturing

The immense complexity of modern biopharmaceutical production is being navigated through the strategic and systematic application of bioprocess analytics improving biologics manufacturing. By leveraging real-time data streams and advanced monitoring tools, manufacturers can gain a granular, molecular-level understanding of cellular behavior and the surrounding environmental conditions within the bioreactor. This proactive, data-driven approach allows for immediate, automated adjustments that optimize therapeutic yield, ensure absolute product consistency, and significantly streamline the arduous path toward commercial-scale production in a highly regulated global environment.

Cell Therapy Quality Control Improving Clinical Outcomes

The long-term success of advanced medicinal products is fundamentally dependent on a rigorous and comprehensive approach to cell therapy quality control improving clinical outcomes. By implementing stringent, multi-stage testing for identity, purity, potency, and safety, manufacturers can guarantee that every individual dose delivered to a patient meets the highest possible standards of GMP compliance. This systematic and data-driven oversight minimizes clinical risks and enhances the reproducibility of complex treatments, ultimately leading to more predictable and successful therapeutic results in the rapidly evolving field of regenerative medicine.
- Advertisement -

Digital Science, a technology company serving stakeholders across the research ecosystem, welcomes two US-based startups to the Digital Science family of companies: automated reproducibility assessment tool, Ripeta, and data science platform, Gigantum.

Both companies are playing a key role in making scientific research reproducible and more transparent. Ripeta is developing a “credit report” for scientific publications to assess and help improve the transparency needed to effectively communicate research, while Gigantum is an emerging innovator in the area of data science platforms, supporting large-scale, data-oriented scientific research.

Daniel Hook, CEO of Digital Science, said: “Reproducibility of research is one of the critical topics of modern times – if research is to remain trusted by the populations who fund it, then researchers must ensure that their research can be reproduced by others.”

Ripeta
Ripeta, a previous Digital Science Catalyst grant winner, aims to make better science easier by identifying and highlighting the important parts of research that should be transparently presented in a manuscript and other materials. The tool detects the key evidence for and assesses reproducibility in the scientific research industry through software and analytics development; improving evidence-based science and fiscal efficiency of research investments. These tools leverage sophisticated machine-learning and natural language processing algorithms to extract key reproducibility elements from research articles.

Ripeta focuses on assessing the quality of the reporting and robustness of the scientific method rather than the quality of the science. The companyโ€™s long-term goal includes developing a suite of tools across the broader spectrum of sciences to understand and measure the key standards and limitations for scientific reproducibility across the research lifecycle and enable an automated approach to their assessment and dissemination.

Leslie McIntosh, CEO of Ripeta, said: “While technological innovations have accelerated scientific discoveries, they have complicated scientific reporting. Science is hard and reproducibility is important, so we need to make better science easier.

“We are developing the tools to make research methods transparent, enabling the verifiability, falsifiability and reproducibility of research. We are thrilled to receive this investment with the great team at Digital Science who provide a fantastic partnership. This will propel our work at Ripeta helping make scientific reporting more transparent.”

Gigantum
Gigantum is a completely new approach to handling the interaction between code, data and run-time environments in this new data-rich research world. Focused on open-source tools and frameworks, Gigantum helps researchers to better scale the creation, management and dissemination of fully reproducible research and the data science that supports it.

Gigantum seeks to develop a platform that keeps pace with the expanding number of independently created tools and data sources, thereby serving an increasingly diverse but collaborative set of researchers with non-uniform skills, interests, and resources. The teamโ€™s technical approach is based on their appreciation that the automated management of data, code, environment, and version history is fundamental to enabling decentralized collaboration.

Dean Kleissas, Gigantum CTO, said: “Despite wide adoption of open-source tools and growing willingness to share research code and data, we still canโ€™t quite escape the evolving difficulties of publishing transparent and easily reproducible research for broad use and consumption.

“When we first spoke with Digital Science, I knew it was a good fit because we immediately clicked on the fact that best practices alone wonโ€™t do it. We need technological approaches that enable real changes in what people of all skill levels can do, not just the most skilled.”

Reproducibility
“Gigantum and Ripeta together address two of the biggest aspects of reproducibility: workflow and communication. Through Gigantum, a researcher can ensure that they have the full provenance of the data objects that appear in their papers, allowing anyone to repeat their data processing and analysis with ease,” adds Hook.

“With Ripeta, a researcher is able to check that they have correctly described and referred to the data, methodology and analysis approaches that underpin their arguments.”

About Digital Science
Digital Science is a technology company working to make research more efficient. We invest in, nurture and support innovative businesses and technologies that make all parts of the research process more open and effective. Our portfolio includes admired brands including Altmetric, Anywhere Access, Dimensions, Figshare, ReadCube, Symplectic, IFI Claims, GRID, Overleaf, Labguru, BioRAFT, TetraScience, Transcriptic and CC Technology. We believe that together, we can help researchers make a difference. Visit www.digital-science.com


About Gigantum
Gigantum is a Washington, DC-based company that is developing a decentralized, scalable and user-friendly data science platform that solves outstanding collaboration and reproducibility problems for both producers and consumers of scientific research. The Gigantum Platform combines a user-friendly open source work environment with a scalable cloud-based publishing platform, allowing researchers to work locally but share globally with a single click. Visit www.gigantum.com


About Ripeta
Ripeta detects and predicts reproducibility in the scientific research industry through software and analytics development; improving evidence-based science and fiscal efficiency of research investments. It is effectively a โ€˜credit reportโ€™ for scientific publications. Ripeta provides a suite of tools and services to rapidly screen and assesses manuscripts for the proper reporting of scientific method components. These tools leverage sophisticated machine-learning and natural language processing algorithms to extract key reproducibility elements from research articles. Visit https://www.ripeta.com/

World Pharma Today brings together the global pharmaceutical industry โ€” from R&D leaders and regulatory affairs professionals to manufacturers and distribution executives โ€” through trusted editorial, market intelligence, and digital engagement.

Our 2026 Media Pack offers integrated solutions to reach your audience:

  • Magazine & Digital Editions Showcase your brand within premium pharmaceutical industry coverage read by executives and decision - makers worldwide.
  • Industry Insights & Reports Align with data - driven analysis, trend reports, and regional roundups across the global pharmaceutical and life sciences value chain.
  • Brand Authority & Credibility Position your company as a thought leader through expert commentary, interviews, and special features.

Latest stories

Related stories

QIAGEN and NVIDIA Join Forces to Advance AI-Driven Drug Discovery

QIAGEN's Digital Insights bioinformatics division is set to integrate...

Bioprocess Analytics Improving Biologics Manufacturing

The immense complexity of modern biopharmaceutical production is being navigated through the strategic and systematic application of bioprocess analytics improving biologics manufacturing. By leveraging real-time data streams and advanced monitoring tools, manufacturers can gain a granular, molecular-level understanding of cellular behavior and the surrounding environmental conditions within the bioreactor. This proactive, data-driven approach allows for immediate, automated adjustments that optimize therapeutic yield, ensure absolute product consistency, and significantly streamline the arduous path toward commercial-scale production in a highly regulated global environment.

Cell Therapy Quality Control Improving Clinical Outcomes

The long-term success of advanced medicinal products is fundamentally dependent on a rigorous and comprehensive approach to cell therapy quality control improving clinical outcomes. By implementing stringent, multi-stage testing for identity, purity, potency, and safety, manufacturers can guarantee that every individual dose delivered to a patient meets the highest possible standards of GMP compliance. This systematic and data-driven oversight minimizes clinical risks and enhances the reproducibility of complex treatments, ultimately leading to more predictable and successful therapeutic results in the rapidly evolving field of regenerative medicine.

GMP Cytokines Advancing Cell Therapy Manufacturing

The rapid transition of cell-based treatments from the experimental laboratory stage to the standard of clinical care is being enabled by the availability of GMP cytokines advancing cell therapy manufacturing. These vital signaling molecules are absolutely essential for the successful expansion, specific differentiation, and functional activation of therapeutic cell populations, such as CAR T cells used in oncology. By strictly adhering to Good Manufacturing Practice standards, suppliers ensure that these critical raw materials possess the high purity, consistent potency, and clinical safety required for human applications, thereby reducing product variability and significantly enhancing the success rate of regenerative medicine.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access theMedia Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Translate ยป